---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-103175"
form_type: "8-K"
ticker: "HIND"
cik: "0001427570"
company_name: "Vyome Holdings, Inc"
filed_at: "2023-09-22T23:59:59+00:00"
generated_at: "2026-06-10T09:38:01.291434+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ReShape Lifesciences signs exclusive license for Obalon balloon in South Asia

## Summary
- Exclusive license to Biorad Medysis for Obalon balloon in India, Pakistan, Bangladesh, Nepal, Bhutan, Sri Lanka, Maldives.
- $200,000 upfront plus 4% royalty on gross sales.
- Biorad to become exclusive worldwide manufacturer under future supply agreement.
- Territory covers ~20-25% of world population (~1.6-2 billion people).

## SEC filing metadata
- accession: 0001104659-23-103175
- form_type: 8-K
- ticker: HIND
- cik: 0001427570
- company_name: Vyome Holdings, Inc
- filed_at: 2023-09-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1427570/000110465923103175/0001104659-23-103175-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1427570/000110465923103175/tm2326688d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-103175
- JSON: https://secwatch.observer/filing/0001104659-23-103175.json
- Plain text: https://secwatch.observer/filing/0001104659-23-103175.txt

## Key facts
- Material Agreements
  Vyome Holdings, Inc entered into License Agreement with Biorad Medysis Pvt. Ltd. valued at $200,000 in upfront payments (effective 2023-09-19).
  - Action: entry
  - Agreement: license
  - Counterparty: Biorad Medysis Pvt. Ltd.
  - Value: $200,000 in upfront payments
  - Effective: 2023-09-19
  source text: On September 19, 2023, ReShape Lifesciences Inc. (the “Company”) entered into an Exclusive License Agreement (the “License Agreement”) with Biorad Medysis Pvt. Ltd. (“Biorad”), pursuant to which the Company granted an exclusive license to Biorad to manufacture, commercialize and distribute the Company’s Obalon® Gastric Balloon System in the territory of India, Pakistan, Bangladesh, Nepal, Bhutan, Sri Lanka, and the Maldives.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1427570/000110465923103175/0001104659-23-103175-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.